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In this paper, we report studies concerning thrombin binding aptamer (tBA) dimeric derivatives in 
which the 3′-ends of two tBA sequences have been joined by means of linkers containing adenosine 
or thymidine residues and/or a glycerol moiety. CD and electrophoretic investigations indicate that all 
modified aptamers are able to form G-quadruplex domains resembling that of the parent TBA structure. 
However, isothermal titration calorimetry measurements of the aptamer/thrombin interaction point to 
different affinities to the target protein, depending on the type of linker. Consistently, the best ligands 
for thrombin show anticoagulant activities higher than tBA. Interestingly, two dimeric aptamers with 
the most promising properties also show far higher resistances in biological environment than tBA.
Nucleic acid aptamers are DNA or RNA ligands characterized by high affinity and specificity to their target mol-
ecules, which can be both proteins, and small molecules. Due to their favorable properties, aptamers can find 
applications in many fields including diagnostics and therapeutics1. Although these ligands can be discovered 
by different strategies, in general, they are selected through combinatorial techniques, overall called SELEX2. 
However, a DNA or RNA ligand molecule discovered by SELEX techniques can be rarely used unmodified, 
mainly because of the poor resistance of natural oligonucleotides in biological environments. For these rea-
sons, the original aptamer sequence is often subject to post-SELEX modifications aimed at improving their gen-
eral properties such as, affinity and specificity toward the target, thermal stability, and resistance to ubiquitous 
endo- and exonucleases3. The most common chemical modifications include introduction of modified bases, 
sugar-phosphate backbone alteration and conjugation with other molecules. A minor number of researches 
have been devoted to aptamer dimerization or multivalent aptamer construction4 which consist in the design 
of ligands with two or more binding domains to the target, although these structural modifications have been 
proven to provide the new construct ligands with better properties than the original aptamer. For example, in 
2008 Hasegawa et al. described a dimeric anti-VEGF (vascular endothelial growth factor) aptamer showing a 
lower dissociation constant value than that of the parent monomer5. In a previous research, multivalent circular 
aptamers against thrombin were designed and assembled, displaying improved anticoagulant potencies with EC50 
values better than that of the canonical GS-522 thrombin DNA aptamer6. Two further anticoagulant aptamers, 
namely the G-quadruplex thrombin binding aptamer (TBA, also called HD1, Fig. 1 and Table 1), and HD22, were 
subject to dimerization through the formation of a stable poly-A/poly-T duplex joining their binding domains by 
hybridization (aptabody)7,8. TBA represents also the precursor of one of the most simple and interesting dimeric 
aptamer, namely the 31-mer RA-36 (Fig. 1 and Table 1), in which two TBA pharmacophore modules are con-
nected through a thymidine residue. The properties of RA-36 have been extensively investigated in comparison 
with other anti-thrombin aptamers9–13. Collected data have shown that RA-36 is an efficient thrombin inhibitor 
with a dose-dependent effect. Furthermore, animal tests have suggested a species-specificity of RA-369,10. In a fur-
ther study the antithrombotic activity of RA-36 has been evaluated by a murine thrombosis model12. Moreover, its 
pharmacodynamic and pharmacokinetic properties have been widely evaluated13. Interestingly, truncation stud-
ies have shown that the two G-quadruplex domains are not functionally equivalent, having the 5′-G-quadruplex 
module an inhibitory activity higher than the precursor TBA and the 3′-G-quadruplex module11.
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The above described findings have inspired us the design of some dimeric TBA derivatives in which two 
5′-G-quadruplex TBA domains are connected through their 3′-ends by symmetric linkers composed by aden-
osine or thymidine residues and/or a glycerol (abbreviated as Gly) moiety (Figs 1, S1 and Table 1). The design 
of these dimeric aptamers shows the following advantages respect to other anti-thrombin dimeric aptamers: 
(1) they are characterized by the two most active 5′-G-quadruplex domains and, (2) thanks to the inversion of 
polarity, they do not possess free 3′-ends that are susceptible to degradation by the most biologically abundant 
3′-exonucleases. Although the introduction of inversion of polarity sites in G-quadruplex structures was pro-
posed some years ago14–16, only recently this strategy has been successfully used as post-SELEX modification 
to increase the biological stability of TBA17,18 or to modulate its biological activities15,16. In this report, an inver-
sion of polarity site has been exploited to join two G-quadruplex TBA domains. Since TBA has been proven to 
interact with the fibrinogen-recognition exosite (EXO I), this one is most likely the target also in the case of the 
TBA variants here described. The new dimeric aptamers have been investigated by circular dichroism (CD) and 
polyacrylamide gel electrophoresis (PAGE). Moreover, their abilities to bind thrombin have been evaluated by 
isothermal titration calorimetry (ITC), while the anticoagulation activity has been tested by the prothrombin 
time (PT) assay. Finally, the resistance in biological environments has been estimated through a fetal bovine 
serum (FBS) stability assay.
The whole of the data have indicated that all the dimeric aptamers are able to form G-quadruplex structures, 
although the affinity to thrombin depends on the type of linker. Remarkably, most of the dimeric TBA derivatives 
have shown higher anticoagulant activities than those of both TBA and RA-36. Furthermore, all new aptamers 
have shown higher nuclease resistance than TBA and, in some cases, also than RA-36.
Results and Discussion
structural insight into the dimeric tBA derivatives. In order to obtain preliminary structural infor-
mation about the conformation adopted by the dimeric TBA derivatives and evaluate the effects of the symmetric 
linkers or the inversion of polarity site, CD spectra and CD melting and annealing experiments were acquired for 
all derivatives and compared with the data of their natural counterpart TBA.
Figure 1. G-quadruplex structures formed by TBA, RA-36 and the new dimeric TBA analogues. Guanosines 
adopting anti and syn glycosidic conformations are indicated in light blue and purple, respectively. For clarity, 
the loop residues are indicated only by white circles.
Name Sequence Tm (°C) ± 1
TBA 5′-GGTTGGTGTGGTTGG-3′ 33
RA-36 5′-TBA-T-TBA-3′ 32
AA 5′-TBA-A-3′-3′-A-TBA-5′ 37
TT 5′-TBA-T-3′-3′-T-TBA-5′ 33
Gly 5′-TBA-3′-Gly-3′-TBA-5′ 35
AGlyA 5′-TBA-A-3′-Gly-3′-A-TBA-5′ 35
TGlyT 5′-TBA-T-3′-Gly-3′-T-TBA-5′ 29
Table 1. Names, sequences and melting temperatures (Tms) of the ODNs investigated. See Methods section for 
details. Gly is here the abbreviation for glycerol.
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The CD spectrum of the TBA is characterized by two positive bands at 247 and 295 nm and a negative one at 
266 nm. This profile is typical of an antiparallel G-quadruplex structure in which anti and syn guanosines alter-
nate both along the strands and in each G-tetrad. Considering the distinctiveness of this profile, a close compar-
ison between CD spectra of the dimeric TBA derivatives and that of their natural counterpart can be considered 
a useful method to forthrightly estimate the effects of these modifications on the G-quadruplex structure. In par-
ticular, besides some differences concerning the band intensities and negligible dissimilarities relating their wave-
length maxima, the CD spectra of all dimeric derivatives and TBA, (Fig. 2) performed at 10 °C, are quite similar, 
thus exhibiting analogous positive and negative bands, indicative of the formation of antiparallel G-quadruplex 
structures comparable to that of the unmodified aptamer TBA for all the dimeric derivatives.
CD melting and annealing measurements have also been used to evaluate the thermal stability of the modified 
aptamers (Figs 3 and S2). The well-defined sigmoidal CD melting and annealing profiles of the modified TBA 
dimers have confidently allowed us the measurement of the melting temperatures (Tms) (Table 1). A compari-
son of all data shows that while the Tms of TT, Gly, AGlyA and RA-36 can be considered similar to that of the 
unmodified aptamer, taking into account the experimental error, AA is characterized by a slightly higher Tm 
(ΔT = + 4 °C) than the natural counterpart. On the other hand, TGlyT showed a slightly lower Tm (ΔT = −4 °C) 
than TBA. The clear absence of hysteresis between heating and cooling profiles in all cases, indicating fast equi-
librium kinetics of the system in the experimental conditions, would suggest the occurrence of a monomolecular 
G-quadruplex structure.
The ODNs investigated were further analyzed by PAGE and compared with TBA and RA-36 used as references 
(Fig. S3). ODNs TT, Gly, and TGlyT have showed bands with electrophoretic motilities rather similar to that of 
the dimeric TBA derivative RA-36 and quite slower than TBA, thus suggesting that the dimeric G-quadruplexes 
do not form higher ordered structures. Little differences concerning their motilities could be ascribed to the effect 
on the migration rate of the different linkers connecting the twin TBA domains. However, in the case of ODNs 
Figure 2. CD spectra of the investigated ODNs. AA (dark blue), TT (purple), Gly (red), TGlyT (yellow) and 
AGlyA (green). TBA (black) and RA-36 (light blue) ODNs have been introduced as references. See the main 
text and the Methods section for details.
Figure 3. Representative CD melting (blue) and annealing (green) curves of the G-quadruplex formed by AA. 
See the main text and the Methods section for details.
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AA and AGlyA two bands are present, being the minor slow-migrating one characterized by a similar motility 
as RA-36. Since their CD profiles are comparable to that of TBA (Fig. 2) and both their anticoagulant activity 
and affinity to thrombin were preserved (see below), it is reasonable to hypothesize that this electrophoretic 
behaviour does not involve the ability of AA and AGlyA to adopt independent twin “chair-like” G-quadruplex 
structures. Taking into account that both these ODNs have adenosine residues in their linkers, the presence of 
the fast-migrating band could be tentatively explained with the propensity of the purine bases to interact with the 
adjacent G-quadruplex, thus forming prevalent more compact structures. In the cases of Gly, AGlyA and TGlyT 
a further minor band with an electrophoretic motility comparable to that of TBA is scarcely noticeable. This result 
would suggest a higher lability of the Gly-containing linkers that caused a slight degradation in monomers of the 
ODN samples used for the electrophoresis. The evaluation of the resistance of the dimeric TBA derivatives by FBS 
assay (see below) is clearly in agreement with this hypothesis.
evaluation of the aptamer/thrombin interactions. In order to assess and quantify the interaction 
between TBA or its dimeric analogues and human α-thrombin, ITC measurements were performed. Firstly, 
the interaction between TBA and the thrombin was analysed at two different protein concentrations to get 
a more reliable Kd value. In both cases, the evolution of the heat exchange during the titration is indicative 
of a tight binding between the two molecules (Fig. 4A,B). ITC data, after integration and correction of heats 
for dilution, were fitted with the one set of binding sites model. The optimal fitting of the experimental data 
provided a reliable dissociation constant Kd of 8 ± 1 nM. Secondly, all the other ODNs have been studied 
considering the concentration value used in the biological assays. All the TBA dimeric analogs have shown 
to be able to bind thrombin, and in detail ODNs AA, TT (Fig. 4C) and AGlyA show comparable Kd values 
with TBA (Kd = 8 nM), namely 10, 5 and 5 nM, respectively (Fig. S4, Table S1) while RA-36 displays the 
lowest affinity (Kd = 100 nM) (Fig. 4D). Interestingly, ODNs AA and TT present a trend ascribable to an 
exothermic reaction differently from the Gly, AGlyA and TGlyT variants showing an endothermic titration 
profile. Such behavior suggests that the linkers containing a glycerol moiety could be involved in the inter-
action with the thrombin.
Anticoagulant activity. In order to evaluate the anticoagulant properties of the TBA dimeric analogs, the 
ODNs have been subjected to PT assay and their anticoagulant activities have been compared to TBA (Fig. 5). The 
results show that all the aptamers, except TGlyT, display a prolonged PT time at both concentration tested (2 and 
20 µM). However, some differences among the ODNs tested have been found, when compared to TBA. In details, 
at the lowest concentration used i.e 2 µM, the PT detected for TT, AglyA and AA has been 29.6 ± 0.18, 30.5 ± 1.2 
and 32.6 ± 0.32 sec, respectively. These PT values are significantly higher when compared to their natural coun-
terpart TBA (25.7 ± 0.10 sec) and to RA-36 for which a PT value of about 23 sec has been reported12. Otherwise, 
evaluation of PT in plasma incubated with Gly reveals an increased PT value superimposable to that observed 
for TBA. These data are quite in agreement with those regarding the dissociation constant values of the complex 
aptamer/thrombin calculated by ITC (Table S1). Concerning the absence of anticoagulant activity of TGlyT, it 
should be noted that this variant shows both the lowest thermal stability (Table 1) and the highest dissociation 
constant (Table S1), thus clearly indicating that these two negative characteristics contribute in collapsing the bio-
logical activity. Unexpectedly, when the TBA dimeric analogues have been evaluated at the highest concentration 
(20 µM), a reduction of the anticoagulant properties has been detected, compared to TBA. These data suggest a 
negative effect of the concentration that could be due to an increase of the intermolecular interactions among the 
G-quadruplex domains in these conditions.
Resistance in biological environments. In order to test the resistance in biological environments, all the 
TBA dimeric analogues were undergone to a degradation assay in fetal bovine serum (Fig. 6) and analyzed by gel 
electrophoresis. Data indicated that there are still significant amounts of undamaged ODNs AA and TT after 6 h. 
On the contrary, an almost complete degradation is evident for RA-36 after the same time while TBA has been 
proven to degrade totally after only 1 h in the same conditions19. These data can be explained taking into account 
that AA and TT are characterized by only free 5′-ends while TBA and RA-36 have canonical sequences with a 
3′-end more sensitive to nucleases. Unexpectedly, Gly, AGlyA and TGlyT have shown a minor resistance after 6 h 
than the other TBA dimer analogues with an inversion of polarity, although they also exhibit only 5′-ends. The data 
suggest that the linkers containing a glycerol moiety make the molecule less resistant in biological environments.
Methods
Oligonucleotides synthesis and purification. The oligonucleotides in Table 1 were synthesized on a 
Millipore Cyclone Plus DNA synthesizer using solid phase β-cyanoethyl phosphoramidite chemistry at 15 µmol 
scale. For all ODNs an universal support was used. The synthesis of the 3′-5′ tracts was performed by using 
normal 3′-phosphoramidites, whereas the 5′-3′ tracts were synthesized by using 5′-phosphoramidites. For the 
synthesis of modified oligonucleotides containing the glycerol linker, a non-nucleosidic phosphoramidite build-
ing block, synthesized as described in the supplementary material, was coupled to universal solid support before 
using normal 3′-phosphoramidites (Fig. S1). The oligomers were detached from the support and deprotected by 
treatment with concentrated aqueous ammonia at 80 °C overnight. The combined filtrates and washings were 
concentrated under reduced pressure, redissolved in H2O, analyzed and purified by high-performance liquid 
chromatography on a Nucleogel SAX column (Macherey–Nagel, 1000-8/46), using buffer A: 20 mM NaH2PO4/
Na2HPO4 aqueous solution (pH 7.0) containing 20% (v/v) CH3CN and buffer B: 1 M NaCl, 20 mM NaH2PO4/
Na2HPO4 aqueous solution (pH 7.0) containing 20% (v/v) CH3CN; a linear gradient from 0 to 100% B in 45 min 
and a flow rate of 1 ml/min were used. The fractions of the oligomers were collected and successively desalted by 
Sep-pak cartridges (C-18). The isolated oligomers proved to be >98% pure by NMR (Fig. S5).
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Circular dichroism spectroscopy. CD samples of modified oligonucleotides and their natural counterpart 
were prepared at ODN concentration of 50 µM by using PBS (Sigma-Aldrich; 10 mM phosphate buffer, 2.7 mM 
KCl, 137 mM NaCl, pH 7.4) and subjected to the annealing procedure (heating at 90 °C and quickly cooling 
at 4 °C). CD spectra of all quadruplexes and CD melting/annealing curves were registered on a Jasco 715 CD 
spectropolarimeter. For the CD spectra, the wavelength was varied from 220 to 320 nm at 100 nm min−1 scan 
rate, and the spectra recorded with a response of 16 s, at 2.0 nm bandwidth and normalized by subtraction of 
the background scan with buffer. The temperature was kept constant at 5 °C with a thermoelectrically controlled 
cell holder (Jasco PTC-348). CD melting/annealing curves were registered as a function of temperature (range: 
5–80 °C) for all quadruplexes at their maximum Cotton effect wavelengths. The CD data were recorded in a 0.1 cm 
pathlength cuvette with a scan rate of 0.5 °C/min.
Figure 4. Isothermal titration calorimetry data for the binding of thrombin with the various ODNs. (A) 
TBA at 100 μM versus 10 μM thrombin; (B) TBA, (C) TT and (D) RA-36 each at 25 μM versus 2.5 μM 
thrombin. (E) Control: TBA at 25 μM versus buffer. The top and bottom panels report raw and integrated 
data, respectively.
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polyacrylamide gel electrophoresis. All oligonucleotides were analyzed by non-denaturing PAGE. 
Samples annealed in PBS were loaded on a 20% polyacrylamide gel containing Tris–Borate-EDTA (TBE) 2.5x and 
NaCl 50 mM. The run buffer was TBE 1x containing 100 mM NaCl. For all samples, a solution of glycerol/TBE 
1x-100 mM NaCl 2:1 was added just before loading. Electrophoresis was performed at 8 V/cm at a temperature 
close to 10 °C. Bands were visualized by UV shadowing.
Isothermal titration calorimetry. ITC studies were performed at 22 °C with an ITC200 calorimeter 
(MicroCal/GE Healthcare). Before all titration experiments the protein was dialyzed against PBS pH 7.4 and the 
ODNs were resuspended in the same buffer. TBA (25 or 100 μM) and its dimeric analogues AA, TT, Gly, AGlyA, 
TGlyT and RA-36 (25 μM) were titrated into a solution of human α-thrombin (2.5 μM or 10 μM) (Hematologic 
Technologies Inc., HCT-0020)20. To exclude the presence of artifacts due to ligand dilution into the protein buffer, 
ITC measurements were performed by titration of ODNs into the buffer. All data were analyzed and fitted using 
the Microcal Origin version 7.0 software package. Dissociation constants were determined by fitting the data 
using a one-set-of-site-binding model. ITC runs were repeated twice to evaluate the reproducibility of the results.
prothrombin time (pt) assay. PT assay was performed on human plasma accordingly to previous investiga-
tions21–23. Briefly this method relies on the high sensitivity of thromboplastin reagent based on recombinant human 
tissue factors. The addition of recombiplastin to the plasma, in presence of calcium ions, activates the extrinsic pathway 
that culminates with the conversion of fibrinogen into fibrin and therefore with a formation of a solid gel. In our exper-
imental conditions, TBA and the modified aptamers were tested at two different concentration: 2 µM and 20 µM. All 
the ODNs or vehicle (phosphate buffer saline, PBS) were incubated with 100 μl of plasma at 37 °C for 15 min and then 
200 μl of the kit solution containing recombiplastin was added with the consequent activation of the extrinsic pathway. 
The PT measurement was produced in triplicate and the average and the standard error values were calculated and 
expressed as seconds. The basal clotting time was evaluated by measuring the clotting time in presence of vehicle.
Figure 5. PT values of the dimeric TBA analogues and their natural counterpart at 2 and 20 μM and 15 min 
incubation. See Methods section for details. ***p < 0.001 vs. vehicle, °°p < 0.01, °°°p < 0.001 vs. TBA (n = 3).
Figure 6. Stability of the investigated ODNs in 10% fetal bovine serum (FBS), as monitored by non-denaturing 
PAGE. Time points 0, 1, 6 and 24 are in hours. See the Methods section for experimental details.
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Fetal bovine serum assay. Nuclease stability assay of modified oligonucleotides was conducted in 10% 
fetal bovine serum (FBS) diluted with Dulbecco’s Modified Eagle’s Medium (DMEM) at 37 °C. Approximately 
15 nmol of stock solution of each ODN (~3 O.D.U.) was evaporated to dryness under reduced pressure and then, 
incubated with 500 μl 10% FBS at 37 °C. At 0, 1, 6 and 24 h, 125 μl of samples were collected and stored at –20 °C 
for at least 20 min. The samples were evaporated to dryness and then 10 μl of gel loading buffer and 10 μl of auto-
claved water was added. 10 μl of the mixture was used for polyacrylamide gel electrophoresis (PAGE), which 
was carried out at room temperature using 20% polyacrylamide gel in 1 × TBE buffer (Tris-borate-EDTA). The 
degradation patterns on the gel were visualized by UV shadowing.
Conclusion
The dimerization of the active domain is one of the strategies often used to improve the properties of the aptam-
ers. Just like others aptamers, also the TBA, being one of the most investigated aptamers, has been the subject of 
dimerization studies. In particular, the properties of a dimer TBA analogue containing two domains separated 
by a thymidine residue (namely, the 31-mer RA-36) have been extensively investigated. However, since RA-36 is 
a canonical DNA sequence, as the TBA, is easily degraded in biological environments. Furthermore, truncation 
studies have proven that the 5′-G-quadruplex domain of RA-36 contributes to the anticoagulant activity in a 
higher extent than the 3′-G-quadruplex domain. In this frame, we have synthesized five TBA dimeric analogues 
in which two 5′-G-quadruplex domains are connected by their 3′-ends using linkers containing two nucleotides 
and/or a glycerol moiety. CD and PAGE experiments strongly suggest that all sequences are able to form mono-
molecular structures with G-quadruplex domains very similar to the parent TBA. Nevertheless, the type of linker 
can affect both their physical-chemical and biological properties. Most of the dimeric analogues show thermal 
stability comparable to TBA, taking into account the experimental error. However, AA shows a slightly higher Tm 
than TBA, while TGlyT is characterized by a lower Tm than TBA. Concerning the affinity to thrombin evaluated 
by ITC, AA, TT and AGlyA are characterized by dissociation constants with the same order of magnitude as 
TBA. In contrast, the dissociation constant values for Gly and TGlyT are higher than TBA, thus showing that 
these aptamers have a lower affinity to thrombin. Importantly, in the case of RA-36, the ITC measurement has 
indicated an affinity to thrombin far lower than those showed by derivatives AA, TT and AGlyA. The biological 
properties of the TBA analogues at low concentration are quite in agreement with the affinity constants to throm-
bin, with AA, TT and AGlyA showing anticoagulant activities higher than TBA, although a negative effect of the 
concentration has been highlighted. Interestingly, AA and TT have shown also the highest stabilities after 6 h in 
fetal bovine serum, where TBA, RA-36 and the TBA derivatives containing the glycerol moiety have been com-
pletely or partially degraded. Although the clinical development of TBA (or HD1) as an anticoagulant drug has 
been stopped, research on TBA variants with better properties interacting with EXO I is still active, considering 
the major role of this site in the thrombin inhibition24. The whole of our results clearly suggest that the type of 
dimerization we propose is a useful strategy to improve TBA properties.
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